
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells ...
Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancers Pluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in- …